South Africa Ups The Ante On COVID-19 Vaccines IP Waiver
UK Is Under Pressure To Back The Proposal
With the COVID-19 situation spiraling out of control in India, Brazil and other parts of the world, calls for the suspension of IP protections on coronavirus vaccines are growing louder. But the R&D based pharmaceutical industry insists a waiver is not the way forward.
You may also be interested in...
President Biden announced plans to increase vaccination in the US as members of Congress and industry press the administration to take steps to expand global access to COVID-19 vaccines. BIO proposes an alternative to the TRIPS waiver that would expedite export of raw materials and manufacturing supplies.
BIO chief calls US Defense Production Act ‘misguided’ as India seeks more COVID vaccines; America will donate AstraZeneca vaccine – just as soon as the FDA determines it was adequately manufactured.
Coronavirus Notebook: WHO’s Plan For Vaccine Manufacturing In Lower-Income Countries, UK Urged To Back IP Waiver
The UK’s independent vaccines committee has finalized its recommendations for the second phase of the COVID-19 vaccination program, and safety issues with several vaccines are still hitting the headlines.